摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

adenyne propenal | 79251-81-3

中文名称
——
中文别名
——
英文名称
adenyne propenal
英文别名
9-(3-oxoprop-1-enyl)adenine;Adenine propenal;(E)-3-(6-aminopurin-9-yl)prop-2-enal
adenyne propenal化学式
CAS
79251-81-3
化学式
C8H7N5O
mdl
——
分子量
189.176
InChiKey
LYXOMQKQLZJTQN-OWOJBTEDSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.3
  • 重原子数:
    14
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    86.7
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    描述:
    adenyne propenal2,3,4,5,6-pentafluorobenzylhydrazine 以 phosphate buffer 、 乙腈 为溶剂, 生成 腺嘌呤 、 2,3,4,5,6-pentafluorobenzylpyrazole
    参考文献:
    名称:
    Reaction of Malondialdehyde−DNA Adducts with HydrazinesDevelopment of a Facile Assay for Quantification of Malondialdehyde Equivalents in DNA
    摘要:
    Malondialdehyde is a ubiquitous product of lipid peroxidation that reacts with DNA to form premutagenic lesions. Principal among them is pyrimido-[1,2-alpha]purin-10(3H)-one (M(1)G). M(1)G has recently been found to be a reactive electrophile in DNA that couples with amines at basic pH or hydroxylamines at neutral pH. We explored the reaction of M(1)G with hydrazines because of the possibility that the latter could act as bifunctional nucleophiles to strip the malondialdehyde equivalent from DNA. Pentafluorophenylhydrazine reacted rapidly with M(1)G to form a hydrazone conjugate. This hydrazone was stable at room temperature and did not cyclize to form the corresponding pyrazole. In contrast, phenylhydrazine and benzylhydrazine reacted with M(1)G to form phenylpyrazole and benzylpyrazole, respectively. Pentafluorobenzylhydrazine reacted rapidly with M(1)G to form pentafluorobenzylpyrazole and dG in near quantitative yield. This reaction formed the basis for a quantitative assay for the presence of M(1)G or M(1)G equivalents in DNA or protein that utilized gas chromatography/negative chemical ionization mass spectrometry. The assay was extended to the oxopropenyl donors, M(1)A, base propenal, and N-epsilon-3-oxopropenyl-lysine. Analysis of DNA treated with bleomycin demonstrated a linear increase in the level of oxopropenyl groups that plateaued at approximately 1 oxopropenyl group/100 bases at a bleomycin concentration of 200 muM. Parallel analysis of M(1)G in the samples revealed that this adduct represents a small fraction of the total oxopropenyl units generated in DNA by treatment with bleomycin.
    DOI:
    10.1021/tx010105v
  • 作为产物:
    描述:
    参考文献:
    名称:
    新型细胞毒性剂:N-(3-氧代丙-1-烯基)取代的嘧啶和嘌呤的合成及生物活性。
    摘要:
    合成了胸腺嘧啶和胞嘧啶的1-(3-氧代丙-1-烯基)衍生物以及腺嘌呤和鸟嘌呤的相应9-取代衍生物(博来霉素,Fe2 +和O2降解DNA的产物)并测试了其生物学活性。胸腺嘧啶和腺嘌呤化合物对多种肿瘤细胞系具有高度细胞毒性,并抑制培养的HeLa细胞中的大分子合成。主要基于嘧啶衍生物的结构活性研究表明,最有效的抑制作用发生在丙烯基位于2'-脱氧核糖核苷的3-氮原子上时。胸苷,2'-脱氧尿苷和5-碘-2'-脱氧尿苷的3-(3-氧代丙-1-烯基)衍生物有力且选择性地抑制了胸苷向DNA中的掺入(IC50大约等于0。5 microM)与用异氧尿苷观察到的结果相当。该系列中的活性化合物易于与含有伯氨基和巯基的亲核试剂反应。这项研究的结果为开发新型细胞毒剂提供了基础。
    DOI:
    10.1021/jm00374a004
点击查看最新优质反应信息

文献信息

  • Liver cell clones for artifical liver and extracorporeal liver assist device
    申请人:JMS Co., Ltd.
    公开号:EP1063289A1
    公开(公告)日:2000-12-27
    Disclosed is a blood perfusion device or apparatus that is used for bioartificial liver support. Human hepatocyte lines established from normal regenerating liver tissue and modulated in toxin-challenging conditions are provided. These functional hepatocytes exhibit extraordinarily enhanced detoxification functions, which are characterised by the elevated glutathione content and glutathione S-transferase activity. A bioreactor is constructed with the functional hepatocytes for bioartificial liver support system, which includes perfusion inlets and perfusion outlets, a containment vessel, a centrifugal pump and macroporous microcarriers where the functional hepatocytes are grown.
    所公开的是一种用于生物人工肝支持的血液灌流装置或设备。提供了从正常再生肝组织中建立并在毒素挑战条件下调节的人类肝细胞系。这些功能性肝细胞的解毒功能异常增强,其特点是谷胱甘肽含量和谷胱甘肽 S 转移酶活性升高。该系统包括灌注入口和灌注出口、密闭容器、离心泵和生长功能肝细胞的大孔微载体。
  • Bi-functional complexes and methods for making and using such complexes
    申请人:Gouliaev Alex Haahr
    公开号:US11225655B2
    公开(公告)日:2022-01-18
    The present invention is directed to a method for the synthesis of a bi-functional complex comprising a molecule part and an identifier oligonucleotide part identifying the molecule part. A part of the synthesis method according to the present invention is preferably conducted in one or more organic solvents when a nascent bi-functional complex comprising an optionally protected tag or oligonucleotide identifier is linked to a solid support, and another part of the synthesis method is preferably conducted under conditions suitable for enzymatic addition of an oligonucleotide tag to a nascent bi-functional complex in solution.
    本发明涉及一种合成双功能复合物的方法,该复合物包括分子部分和识别分子部分的识别寡核苷酸部分。根据本发明的合成方法的一部分优选在一种或多种有机溶剂中进行,此时包含可选保护标签或寡核苷酸标识符的新生双功能复合物与固体支持物相连接,合成方法的另一部分优选在适合于将寡核苷酸标签酶加到溶液中的新生双功能复合物的条件下进行。
  • JOHNSON, FRANCIS;GROLLMAN, ARTBUR P.
    作者:JOHNSON, FRANCIS、GROLLMAN, ARTBUR P.
    DOI:——
    日期:——
  • BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES
    申请人:Nuevolution A/S
    公开号:EP2558577A1
    公开(公告)日:2013-02-20
  • Oxidoreductase inhibitors and methods of screening and using thereof
    申请人:Balendiran K. Ganesaratnam
    公开号:US20050004225A1
    公开(公告)日:2005-01-06
    The present invention relates to 1) the design and synthesis of analogs to glutathione conjugates which bind to or interact with aldose reductase (AR) through unique conformations that are distinctly different from the substrates and inhibitors of AR which are members of sugar metabolism; 2) the screening of the analogs to identify those that interact with or inhibit or enhance the activity of AR; and 3) the use of AR ligands, AR inhibitors (AR antagonsits) or AR enhancer (AR agonists) in the detection of AR activity, the modulation of AR activity, and the treatment of conditions in a subject in need of modulating AR activity. Such conditions include but not limited to cardiovascular disease, diabetes, artheriosclerosis, cancer, neoplasm, obesity, cataract, retinopathy, keratopathy, nephropathy, neurosis, thrombosis, faulty union of corneal injury and neuropathy. Examples of the treatment include the use of fibrates as AR inhibitors to treat these conditions.
查看更多